At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 4 enrolled
Drug / intervention
Elranatamab (PF-06863135)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETIC OF PF 06863135, A B CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, AS A SINGLE AGENT IN JAPANESE PARTICIPANTS WITH RELAPSED/REFRACTORY ADVANCED MULTIPLE MYELOMA
In Brief
A Phase 1 clinical trial evaluating Elranatamab (PF-06863135) for Relapsed or Refractory Multiple Myeloma. Completed, enrolled 4 participants across 2 sites.
Detailed Summary
The purpose of this study is to confirm the safety and tolerability of elranatamab (PF-06863135) in Japanese participants with relapsed or refractory MM.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed or Refractory Multiple Myeloma
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedMar 2021
Enrollment StartMar 2021
Primary CompletionMay 2022
Study CompletionMay 2023
TodayJul 2026
First PostedMar 15, 2021
Enrollment StartMar 22, 2021
Primary CompletionMay 27, 2022
Study CompletionMay 17, 2023
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.3 years ago
Interventions
Elranatamab (PF-06863135)drug
BCMA-CD3 bispecific antibody